Lab Monkey Prices Surge Amid Supply Shortage
Prices for U.S. research macaques have risen sharply as China's export restrictions tightened supply, prompting a new domestic breeding effort.
Updated on Nov. 2, 2026 in Healthcare
Live Poll
Should the US keep using monkeys in drug safety testing?
The price of lab monkeys in the United States rose from $3,000 to $20,000, an increase of about 570 percent, amid a supply shortage. Humane Medicine, a startup backed by Palantir co-founder Joe Lonsdale, plans to breed tens of thousands of macaques domestically.
Why it matters
China imposed export restrictions on research monkeys during the COVID-19 pandemic, forcing American labs to seek alternative sources. The shortage raises costs for drug developers who rely on primate testing.
Humane Medicine has raised $28 million since its 2023 founding and plans a breeding facility in Bainbridge, Georgia, that could eventually house up to 30,000 long-tailed macaques. Each primate used in a six-month antibody safety study costs $50,000, and such studies typically involve about 144 non-human primates.
The players
Humane Medicine
A startup founded in 2023 that plans to breed up to 30,000 macaques at a facility in Bainbridge, Georgia, and has raised $28 million.
Joe Lonsdale
Palantir co-founder and investor who is backing Humane Medicine's domestic primate breeding effort.
Charles River Laboratories
A major supplier of research animals whose monkey prices rose sharply between 2019 and 2022.
The details
Humane Medicine plans to breed macaques domestically to address the shortage. Female macaques reach sexual maturity around age four and typically give birth to one offspring per year, which limits how fast supply can grow.
Timeline
2019: Lab monkey prices were about $3,000 per monkey.
2020: COVID-19 pandemic prompted China to impose export restrictions on monkeys.
2022: Charles River's monkey price reached $22,000.
2023: Humane Medicine was founded.
Market Landscape
China's 2020 export restrictions on research monkeys during the COVID-19 pandemic cut off a key supply source for American labs. The resulting price spike is now pushing investors like Joe Lonsdale toward building domestic primate breeding capacity.
Higher research animal costs can raise the expense of developing new drugs, which may eventually affect the prices consumers pay for medicines. Domestic breeding could ease supply constraints, but it will take years before it meaningfully reduces import dependence.
The takeaway
Supply shocks in specialized biomedical inputs can ripple through drug development costs for years. Watching whether domestic breeding scales as planned will show how resilient U.S. research supply chains really are.
Further reading
Explore more on Healthcare industry developments shaping drug research supply chains.
Source note: This article includes information reported by Ajel.
Live Poll
Should the US keep using monkeys in drug safety testing?
